Please Sign In or Create an account
The Epidermal Growth Factor system in schizophrenia and its relation to treatment resistance

The Epidermal Growth Factor system in schizophrenia and its relation to treatment resistance

Up to 45% of patients with schizophrenia are treatment resistant to conventional drugs leaving clozapine as the only effective option. Its severe side-effects however limit it to a late stage option and the development of a biomarker to predict treatment response would be of high clinical utility. Our previous data demonstrate clozapine augments epidermal growth factor receptor (EGFR) signalling and hence we examined if EGF levels may be altered in treatment resistant schizophrenia (TRS) and are influenced by clozapine treatment. To determine if EGF levels are influenced by clozapine in TRS and can serve as a biomarker for clozapine response. Serum EGF levels were measured by ELISA in patients with TRS at baseline, 2, 6 and 26 weeks of clozapine treatment and in age and sexed matched healthy controls. Positive and Negative Syndrome Scale (PANSS) and CGI data were collected at baseline, 6 and 26 weeks.

In the patient group, the mean reduction in total PANSS score was 20.4 and CGI was 1.82 (n=56). Twenty-six (46%) patients responded (=20% reduction in PANSS score). Mean EGF levels at base line were 272pg/ml (±223, SD), at 2weeks 242pg/ml (±190), at 6 weeks 400pg/ml (±228) and at 26 weeks 409pg/ml (±275). These values were significantly (p<0.01) lower than that of the controls (mean 749pg/ml ±328). Mean EGF levels increased over the 26 weeks in patients by 169% (±269) and this became significant by 6 (P=0.013) and 26 weeks (P=0.019). There were no significant main correlations between EGF levels and clinical response.  EGF levels were significantly decreased in people with TRS and were significantly increased with clozapine treatment indicating that clozapine is able to modulate the EGF system in patients. There was however no relationship with symptom change suggesting it is unlikely to be a suitable biomarker for clozapine response.

Conference: MAPrc
Areas of Interest / Categories: Monash Alfred Psychiatry Research Centre 2015

Monash Alfred Psychiatry Research Centre 2015

Maternal immune activation impacts on the kynurenine pathway in preadolescent offspring: Preventive effects of anti-inflammatory treatment.

Kynurenic acid (KYNA), a glia-derived metabolite of the kynurenine pathway (KP) of tryptophan degradation, is an antagonist at glutamate NMDA and a7 nicotinic acetylcholine receptors. Abnormalities in the KP have been described in patients with schizophrenia. Cyclo-oxygenese-2 (COX-2) inhibitors show considerable promise in treating early (but not late) stage schizophrenia and preclinical studies suggest that COX-2 inhibitors decrease KYNA in the brain.

Altered cell migration in patient-derived stem cell model of schizophrenia.

Evidence from genetic association studies implicate genes involved in neural migration associated with schizophrenia risk. Neural stem/progenitor cell cultures (neurosphere-derived cells) from olfactory mucosa of schizophrenia patients have significantly dysregulated expression of genes in focal adhesion kinase signalling, a key pathway regulating cell adhesion and migration. The aim of this study was to investigate whether olfactory neurosphere-derived cells from schizophrenia patients have altered cell adhesion, cell motility, and focal adhesion dynamics. Olfactory neurosphere-derived cells from nine male schizophrenia patients and nine male healthy control subjects were used. Cells were assayed for cell adhesion and cell motility and analysed for integrins and focal adhesion kinase proteins. Focal adhesions were counted and measured in fixed cells and time-lapse imaging was used to assess cell motility and focal adhesion dynamics.

Interaction of maternal immune activation and adolescent cannabinoid exposure enhances changes in miRNA expression in the adult entorhinal cortex.

Post-mortem analyses of cortical brain tissue in schizophrenia have been shown to display epigenetic changes that reflect early life experience. These affect the regulation of gene expression at the level of transcription, through changes in chromatin structure; and post-transcriptionally through non-coding RNAs, such as microRNA (miRNA). The aim of the current study was to investigate the role of miRNA in the brains’ response to maternal immune activation and adolescent cannabis exposure, alone and in combination, as both have been identified as environmental risk factors for schizophrenia.

Can Neuropsychological Profile (RBANS) Predict Co-Morbid Traumatic Brain Injury and Psychosis?

NOTE: Only available in Mp3 audio file. Traumatic insanity has been acknowledged since Meyer (1904), however, Psychosis Following Traumatic Brain Injury (PFTBI) has received modest empirical investigation, and is subsequently poorly understood, identified, and treated. Systematic and standardised neuropsychological research of PFTBI has not been reported, with work relying on retrospective chart reviews, case studies, and loosely defined self-reported Traumatic Brain Injury (TBI).

Common polymorphisms in dopamine related genes combine to produce a “schizophrenia-like” prefrontal hypoactivity

The dopamine system plays a crucial role in mediating cognitive and affective processes. Aberrant dopamine neurotransmission is also thought to underlie the symptoms of schizophrenia. Dopamine-dependent prefrontal response relies on the regulation of both dopamine availability and the relative balance of D1/D2 receptor mediated action. This study aimed to determine the extent to which the catechol-O-methyltransferase (COMT) val108/158met (rs4680) and dopamine D2 receptor (DRD2) G-T (rs2283265) polymorphisms combine additively to determine prefrontal brain activity during cognitive-affective processing in healthy people and in schizophrenia.